The Experts below are selected from a list of 44643 Experts worldwide ranked by ideXlab platform
Adriana Baz Morelli - One of the best experts on this subject based on the ideXlab platform.
-
Therapeutic ISCOMATRIX™ adjuvant vaccine elicits effective anti-tumor immunity in the TRAMP-C1 mouse model of prostate cancer
Cancer Immunology Immunotherapy, 2020Co-Authors: Adele M. Barr, Anabel Silva, Sandro Prato, Gabrielle T. Belz, Eugene Maraskovsky, Adriana Baz MorelliAbstract:Cancer vaccine development has proven challenging with the exception of some virally induced cancers for which prophylactic vaccines exist. Currently, there is only one FDA approved vaccine for the treatment of prostate cancer and as such prostate cancer continues to present a significant unmet medical need. In this study, we examine the effectiveness of a therapeutic cancer vaccine that combines the ISCOMATRIX™ adjuvant (ISCOMATRIX) with the Toll-like receptor 3 agonist, polyinosinic–polycytidylic acid (Poly I:C), and Flt3L, FMS-like tyrosine kinase 3 ligand. We employed the TRAMP-C1 (transgenic adenocarcinoma of the mouse prostate) model of prostate cancer and the self-protein mPAP (prostatic acid phosphatase) as the tumor antigen. ISCOMATRIX™–mPAP–Poly I:C–Flt3L was delivered in a therapeutic prime-boost regime that was consistently able to achieve complete tumor regression in 60% of animals treated and these tumor-free animals were protected upon rechallenge. Investigations into the underlying immunological mechanisms contributing to the effectiveness of this vaccine identified that both innate and adaptive responses are elicited and required. NK cells, CD4^+ T cells and interferon-γ were all found to be critical for tumor control while tumor infiltrating CD8^+ T cells became disabled by an immunosuppressive microenvironment. There is potential for broader application of this cancer vaccine, as we have been able to demonstrate effectiveness in two additional cancer models; Melanoma (B16-OVA) and a model of B cell lymphoma (Eµ-myc-GFP-OVA).
-
Therapeutic ISCOMATRIX™ adjuvant vaccine elicits effective anti-tumor immunity in the TRAMP-C1 mouse model of prostate cancer
Cancer Immunology Immunotherapy, 2020Co-Authors: Adele M. Barr, Anabel Silva, Sandro Prato, Gabrielle T. Belz, Eugene Maraskovsky, Adriana Baz MorelliAbstract:Cancer vaccine development has proven challenging with the exception of some virally induced cancers for which prophylactic vaccines exist. Currently, there is only one FDA approved vaccine for the treatment of prostate cancer and as such prostate cancer continues to present a significant unmet medical need. In this study, we examine the effectiveness of a therapeutic cancer vaccine that combines the ISCOMATRIX™ adjuvant (ISCOMATRIX) with the Toll-like receptor 3 agonist, polyinosinic–polycytidylic acid (Poly I:C), and Flt3L, FMS-like tyrosine kinase 3 ligand. We employed the TRAMP-C1 (transgenic adenocarcinoma of the mouse prostate) model of prostate cancer and the self-protein mPAP (prostatic acid phosphatase) as the tumor antigen. ISCOMATRIX™–mPAP–Poly I:C–Flt3L was delivered in a therapeutic prime-boost regime that was consistently able to achieve complete tumor regression in 60% of animals treated and these tumor-free animals were protected upon rechallenge. Investigations into the underlying immunological mechanisms contributing to the effectiveness of this vaccine identified that both innate and adaptive responses are elicited and required. NK cells, CD4^+ T cells and interferon-γ were all found to be critical for tumor control while tumor infiltrating CD8^+ T cells became disabled by an immunosuppressive microenvironment. There is potential for broader application of this cancer vaccine, as we have been able to demonstrate effectiveness in two additional cancer models; Melanoma (B16-OVA) and a model of B cell lymphoma (Eµ-myc-GFP-OVA).
Adele M. Barr - One of the best experts on this subject based on the ideXlab platform.
-
Therapeutic ISCOMATRIX™ adjuvant vaccine elicits effective anti-tumor immunity in the TRAMP-C1 mouse model of prostate cancer
Cancer Immunology Immunotherapy, 2020Co-Authors: Adele M. Barr, Anabel Silva, Sandro Prato, Gabrielle T. Belz, Eugene Maraskovsky, Adriana Baz MorelliAbstract:Cancer vaccine development has proven challenging with the exception of some virally induced cancers for which prophylactic vaccines exist. Currently, there is only one FDA approved vaccine for the treatment of prostate cancer and as such prostate cancer continues to present a significant unmet medical need. In this study, we examine the effectiveness of a therapeutic cancer vaccine that combines the ISCOMATRIX™ adjuvant (ISCOMATRIX) with the Toll-like receptor 3 agonist, polyinosinic–polycytidylic acid (Poly I:C), and Flt3L, FMS-like tyrosine kinase 3 ligand. We employed the TRAMP-C1 (transgenic adenocarcinoma of the mouse prostate) model of prostate cancer and the self-protein mPAP (prostatic acid phosphatase) as the tumor antigen. ISCOMATRIX™–mPAP–Poly I:C–Flt3L was delivered in a therapeutic prime-boost regime that was consistently able to achieve complete tumor regression in 60% of animals treated and these tumor-free animals were protected upon rechallenge. Investigations into the underlying immunological mechanisms contributing to the effectiveness of this vaccine identified that both innate and adaptive responses are elicited and required. NK cells, CD4^+ T cells and interferon-γ were all found to be critical for tumor control while tumor infiltrating CD8^+ T cells became disabled by an immunosuppressive microenvironment. There is potential for broader application of this cancer vaccine, as we have been able to demonstrate effectiveness in two additional cancer models; Melanoma (B16-OVA) and a model of B cell lymphoma (Eµ-myc-GFP-OVA).
-
Therapeutic ISCOMATRIX™ adjuvant vaccine elicits effective anti-tumor immunity in the TRAMP-C1 mouse model of prostate cancer
Cancer Immunology Immunotherapy, 2020Co-Authors: Adele M. Barr, Anabel Silva, Sandro Prato, Gabrielle T. Belz, Eugene Maraskovsky, Adriana Baz MorelliAbstract:Cancer vaccine development has proven challenging with the exception of some virally induced cancers for which prophylactic vaccines exist. Currently, there is only one FDA approved vaccine for the treatment of prostate cancer and as such prostate cancer continues to present a significant unmet medical need. In this study, we examine the effectiveness of a therapeutic cancer vaccine that combines the ISCOMATRIX™ adjuvant (ISCOMATRIX) with the Toll-like receptor 3 agonist, polyinosinic–polycytidylic acid (Poly I:C), and Flt3L, FMS-like tyrosine kinase 3 ligand. We employed the TRAMP-C1 (transgenic adenocarcinoma of the mouse prostate) model of prostate cancer and the self-protein mPAP (prostatic acid phosphatase) as the tumor antigen. ISCOMATRIX™–mPAP–Poly I:C–Flt3L was delivered in a therapeutic prime-boost regime that was consistently able to achieve complete tumor regression in 60% of animals treated and these tumor-free animals were protected upon rechallenge. Investigations into the underlying immunological mechanisms contributing to the effectiveness of this vaccine identified that both innate and adaptive responses are elicited and required. NK cells, CD4^+ T cells and interferon-γ were all found to be critical for tumor control while tumor infiltrating CD8^+ T cells became disabled by an immunosuppressive microenvironment. There is potential for broader application of this cancer vaccine, as we have been able to demonstrate effectiveness in two additional cancer models; Melanoma (B16-OVA) and a model of B cell lymphoma (Eµ-myc-GFP-OVA).
Sang-hun Jung - One of the best experts on this subject based on the ideXlab platform.
-
refinement of the pharmacophore of 3 4 dihydroquinazoline 2 1h thiones for their anti melanogenesis activity
ChemInform, 2011Co-Authors: Pillaiyar Thanigaimalai, Vinay K. Sharma, Sang-hun JungAbstract:In order to define structural requirements, novel quinazolines, e.g. (IV), are synthesized and their anti-melanogenesis activity is evaluated using Melanoma B16 cells under the stimulant of α-MSH.
-
novel benzo d imidazole 2 3h thiones as potent inhibitors of the α melanocyte stimulating hormone induced melanogenesis in Melanoma B16 cells
ChemInform, 2011Co-Authors: Jee Hyun Lee, Pillaiyar Thanigaimalai, Seong Cheol Bang, Vinay K. Sharma, Youngsoo Kim, Kicheul Lee, Minseok Kim, Cheong Yong Yun, Eunmiri Roh, Sang-hun JungAbstract:A variety of novel benzimidazolones and related-thiones is synthesized and evaluated for inhibitory activities against melanin production in Melanoma B16 cells.
-
refinement of the pharmacophore of 3 4 dihydroquinazoline 2 1h thiones for their anti melanogenesis activity
Bioorganic & Medicinal Chemistry Letters, 2010Co-Authors: Pillaiyar Thanigaimalai, Vinay K. Sharma, Sang-hun JungAbstract:Abstract In order to define the structural requirements of quinazoline-2(1 H )-thiones 1 for their inhibitory activity on melanogenesis, a novel series of 3,4-dihydroquinazoline-2(1 H )-thiones ( 3a – h ) were prepared and screened for their melanogenesis inhibition on Melanoma B16 cell line under the stimulant of α-MSH. The anti-melanogenesis activity of 3 is mainly mediated by the hydrogen bonding ability of thioamide unit in addition to complexation ability of thione and the hydrophobic binding power of side chain substitutions at 3-position. Thus, the pharmacophore of 3,4-dihydroquinazoline-2(1 H )-thiones for their anti-melanogenesis activity could be refined as 3-hydrophobic substituted quinazolinethione.
-
evaluation of 3 4 dihydroquinazoline 2 1h thiones as inhibitors of α msh induced melanin production in Melanoma B16 cells
Bioorganic & Medicinal Chemistry, 2010Co-Authors: Pillaiyar Thanigaimalai, Seong Cheol Bang, Bang Yeon Hwang, Sang-hun JungAbstract:Abstract Novel 3,4-dihydroquinazoline-2(1 H )-thiones (QNTs) 1 were found to be potent inhibitors of α-MSH-induced melanin production. The effect of QNTs to inhibit melanin formation in B16 Melanoma cells was screened in the presence of α-MSH. In defining the mechanism of activity, the effects on tyrosinase activity, on tyrosinase synthesis and on the depigmentation of melanin were evaluated. QNTs did not affect the catalytic activity of tyrosinase, but rather acted as an inhibitor of tyrosinase synthesis.
-
Inhibitory effect of novel tetrahydropyrimidine-2(1H)-thiones on melanogenesis.
Bioorganic & Medicinal Chemistry, 2009Co-Authors: Pillaiyar Thanigaimalai, Seong Cheol Bang, Bang Yeon Hwang, Sang-hun JungAbstract:Abstract The series of imidazoldine-2-thiones 2 and tetrahydropyrimidine-2-thiones 3 were discovered as inhibitor of α-MSH-induced melanin production in Melanoma B16 cells. The primary bioassay showed that 1-(4-ethylbenzyl)-tetrahydropyrimidine-2(1H)-thione 3e (>100% inhibition at 10 μM, IC50 = 1.2 μM) and 1-(4-tert-butylbenzyl)-tetrahydropyrimidine-2(1H)-thione 3f (>100% inhibition at 10 μM, IC50 = 0.76 μM) exhibited potent inhibitory effect against α-MSH-induced melanin production. Compounds 3 inhibit the biosynthesis of tyrosinase without affecting its catalytic activity in melanogenesis.
Eugene Maraskovsky - One of the best experts on this subject based on the ideXlab platform.
-
Therapeutic ISCOMATRIX™ adjuvant vaccine elicits effective anti-tumor immunity in the TRAMP-C1 mouse model of prostate cancer
Cancer Immunology Immunotherapy, 2020Co-Authors: Adele M. Barr, Anabel Silva, Sandro Prato, Gabrielle T. Belz, Eugene Maraskovsky, Adriana Baz MorelliAbstract:Cancer vaccine development has proven challenging with the exception of some virally induced cancers for which prophylactic vaccines exist. Currently, there is only one FDA approved vaccine for the treatment of prostate cancer and as such prostate cancer continues to present a significant unmet medical need. In this study, we examine the effectiveness of a therapeutic cancer vaccine that combines the ISCOMATRIX™ adjuvant (ISCOMATRIX) with the Toll-like receptor 3 agonist, polyinosinic–polycytidylic acid (Poly I:C), and Flt3L, FMS-like tyrosine kinase 3 ligand. We employed the TRAMP-C1 (transgenic adenocarcinoma of the mouse prostate) model of prostate cancer and the self-protein mPAP (prostatic acid phosphatase) as the tumor antigen. ISCOMATRIX™–mPAP–Poly I:C–Flt3L was delivered in a therapeutic prime-boost regime that was consistently able to achieve complete tumor regression in 60% of animals treated and these tumor-free animals were protected upon rechallenge. Investigations into the underlying immunological mechanisms contributing to the effectiveness of this vaccine identified that both innate and adaptive responses are elicited and required. NK cells, CD4^+ T cells and interferon-γ were all found to be critical for tumor control while tumor infiltrating CD8^+ T cells became disabled by an immunosuppressive microenvironment. There is potential for broader application of this cancer vaccine, as we have been able to demonstrate effectiveness in two additional cancer models; Melanoma (B16-OVA) and a model of B cell lymphoma (Eµ-myc-GFP-OVA).
-
Therapeutic ISCOMATRIX™ adjuvant vaccine elicits effective anti-tumor immunity in the TRAMP-C1 mouse model of prostate cancer
Cancer Immunology Immunotherapy, 2020Co-Authors: Adele M. Barr, Anabel Silva, Sandro Prato, Gabrielle T. Belz, Eugene Maraskovsky, Adriana Baz MorelliAbstract:Cancer vaccine development has proven challenging with the exception of some virally induced cancers for which prophylactic vaccines exist. Currently, there is only one FDA approved vaccine for the treatment of prostate cancer and as such prostate cancer continues to present a significant unmet medical need. In this study, we examine the effectiveness of a therapeutic cancer vaccine that combines the ISCOMATRIX™ adjuvant (ISCOMATRIX) with the Toll-like receptor 3 agonist, polyinosinic–polycytidylic acid (Poly I:C), and Flt3L, FMS-like tyrosine kinase 3 ligand. We employed the TRAMP-C1 (transgenic adenocarcinoma of the mouse prostate) model of prostate cancer and the self-protein mPAP (prostatic acid phosphatase) as the tumor antigen. ISCOMATRIX™–mPAP–Poly I:C–Flt3L was delivered in a therapeutic prime-boost regime that was consistently able to achieve complete tumor regression in 60% of animals treated and these tumor-free animals were protected upon rechallenge. Investigations into the underlying immunological mechanisms contributing to the effectiveness of this vaccine identified that both innate and adaptive responses are elicited and required. NK cells, CD4^+ T cells and interferon-γ were all found to be critical for tumor control while tumor infiltrating CD8^+ T cells became disabled by an immunosuppressive microenvironment. There is potential for broader application of this cancer vaccine, as we have been able to demonstrate effectiveness in two additional cancer models; Melanoma (B16-OVA) and a model of B cell lymphoma (Eµ-myc-GFP-OVA).
Anabel Silva - One of the best experts on this subject based on the ideXlab platform.
-
Therapeutic ISCOMATRIX™ adjuvant vaccine elicits effective anti-tumor immunity in the TRAMP-C1 mouse model of prostate cancer
Cancer Immunology Immunotherapy, 2020Co-Authors: Adele M. Barr, Anabel Silva, Sandro Prato, Gabrielle T. Belz, Eugene Maraskovsky, Adriana Baz MorelliAbstract:Cancer vaccine development has proven challenging with the exception of some virally induced cancers for which prophylactic vaccines exist. Currently, there is only one FDA approved vaccine for the treatment of prostate cancer and as such prostate cancer continues to present a significant unmet medical need. In this study, we examine the effectiveness of a therapeutic cancer vaccine that combines the ISCOMATRIX™ adjuvant (ISCOMATRIX) with the Toll-like receptor 3 agonist, polyinosinic–polycytidylic acid (Poly I:C), and Flt3L, FMS-like tyrosine kinase 3 ligand. We employed the TRAMP-C1 (transgenic adenocarcinoma of the mouse prostate) model of prostate cancer and the self-protein mPAP (prostatic acid phosphatase) as the tumor antigen. ISCOMATRIX™–mPAP–Poly I:C–Flt3L was delivered in a therapeutic prime-boost regime that was consistently able to achieve complete tumor regression in 60% of animals treated and these tumor-free animals were protected upon rechallenge. Investigations into the underlying immunological mechanisms contributing to the effectiveness of this vaccine identified that both innate and adaptive responses are elicited and required. NK cells, CD4^+ T cells and interferon-γ were all found to be critical for tumor control while tumor infiltrating CD8^+ T cells became disabled by an immunosuppressive microenvironment. There is potential for broader application of this cancer vaccine, as we have been able to demonstrate effectiveness in two additional cancer models; Melanoma (B16-OVA) and a model of B cell lymphoma (Eµ-myc-GFP-OVA).
-
Therapeutic ISCOMATRIX™ adjuvant vaccine elicits effective anti-tumor immunity in the TRAMP-C1 mouse model of prostate cancer
Cancer Immunology Immunotherapy, 2020Co-Authors: Adele M. Barr, Anabel Silva, Sandro Prato, Gabrielle T. Belz, Eugene Maraskovsky, Adriana Baz MorelliAbstract:Cancer vaccine development has proven challenging with the exception of some virally induced cancers for which prophylactic vaccines exist. Currently, there is only one FDA approved vaccine for the treatment of prostate cancer and as such prostate cancer continues to present a significant unmet medical need. In this study, we examine the effectiveness of a therapeutic cancer vaccine that combines the ISCOMATRIX™ adjuvant (ISCOMATRIX) with the Toll-like receptor 3 agonist, polyinosinic–polycytidylic acid (Poly I:C), and Flt3L, FMS-like tyrosine kinase 3 ligand. We employed the TRAMP-C1 (transgenic adenocarcinoma of the mouse prostate) model of prostate cancer and the self-protein mPAP (prostatic acid phosphatase) as the tumor antigen. ISCOMATRIX™–mPAP–Poly I:C–Flt3L was delivered in a therapeutic prime-boost regime that was consistently able to achieve complete tumor regression in 60% of animals treated and these tumor-free animals were protected upon rechallenge. Investigations into the underlying immunological mechanisms contributing to the effectiveness of this vaccine identified that both innate and adaptive responses are elicited and required. NK cells, CD4^+ T cells and interferon-γ were all found to be critical for tumor control while tumor infiltrating CD8^+ T cells became disabled by an immunosuppressive microenvironment. There is potential for broader application of this cancer vaccine, as we have been able to demonstrate effectiveness in two additional cancer models; Melanoma (B16-OVA) and a model of B cell lymphoma (Eµ-myc-GFP-OVA).